These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12067917)

  • 1. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study.
    Lev EI; Marmur JD; Zdravkovic M; Osende JI; Robbins J; Delfin JA; Richard M; Erhardtsen E; Thomsen MS; Lincoff AM; Badimon JJ
    Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1036-41. PubMed ID: 12067917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury.
    Söderström T; Hedner U; Arnljots B
    J Vasc Surg; 2001 May; 33(5):1072-9. PubMed ID: 11331851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood.
    Orvim U; Barstad RM; Orning L; Petersen LB; Ezban M; Hedner U; Sakariassen KS
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3049-56. PubMed ID: 9409292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-thrombotic and haemorrhagic effects of active site-inhibited factor VIIa in rats.
    Ghrib F; Léger P; Ezban M; Kristensen A; Cambus J; Boneu B
    Br J Haematol; 2001 Feb; 112(2):506-12. PubMed ID: 11167855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.
    Lev EI; Patel R; Karim A; Kleiman A; Badimon JJ; Kleiman NS
    Thromb Haemost; 2006 Mar; 95(3):441-6. PubMed ID: 16525571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local application of FFR-rFVIIa reduces thrombus formation at arterial anastomosis in rats.
    Sørensen HB; Kristensen AT; Ravn HB; Fuglsang J; Hjortdal VE
    Microsurgery; 1999; 19(8):369-73. PubMed ID: 10594911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.
    Moons AH; Peters RJ; Bijsterveld NR; Piek JJ; Prins MH; Vlasuk GP; Rote WE; Büller HR
    J Am Coll Cardiol; 2003 Jun; 41(12):2147-53. PubMed ID: 12821239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.
    Holst J; Kristensen AT; Kristensen HI; Ezban M; Hedner U
    Eur J Vasc Endovasc Surg; 1998 Jun; 15(6):515-20. PubMed ID: 9659887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
    Erhardtsen E; Nilsson P; Johannessen M; Thomsen MS
    J Clin Pharmacol; 2001 Aug; 41(8):880-5. PubMed ID: 11504276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome.
    Vincent JL; Artigas A; Petersen LC; Meyer C
    Crit Care Med; 2009 Jun; 37(6):1874-80. PubMed ID: 19384216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rFVIIai in Acute Coronary Syndromes.
    Sorensen BB; Hedner U; Erhardtsen E
    Semin Vasc Med; 2003 May; 3(2):199-204. PubMed ID: 15199483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
    Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
    Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
    Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
    Hedner U; Erhardtsen E
    Ann Med; 2000 Dec; 32 Suppl 1():68-72. PubMed ID: 11209985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.
    Roqué M; Reis ED; Fuster V; Padurean A; Fallon JT; Taubman MB; Chesebro JH; Badimon JJ
    J Am Coll Cardiol; 2000 Dec; 36(7):2303-10. PubMed ID: 11127477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.
    Badimon JJ; Lettino M; Toschi V; Fuster V; Berrozpe M; Chesebro JH; Badimon L
    Circulation; 1999 Apr; 99(14):1780-7. PubMed ID: 10199872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury.
    Roqué M; Rauch U; Reis ED; Chesebro JH; Fuster V; Badimon JJ
    Thromb Res; 2000 Jun; 98(6):499-505. PubMed ID: 10899349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
    Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
    Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.